Clinical trialNCT05292664RecruitingPhase 1Interventional

Venetoclax Basket Trial for High Risk Hematologic Malignancies

SponsorAndrew E. Place, MDEnrollment30Acute Leukemia of Ambiguous LineageAcute Leukemia of Ambiguous Lineage in RelapseAcute Lymphoblastic Leukemia With Failed RemissionAcute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma, RefractoryLymphoblastic Lymphoma, in Relapse+5 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic syndrome (MDS/AML), and acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL). The names of the study drugs involved in this study are below. Please note this is a list for the study as a whole, participants will receive drugs according to disease cohort. * Venetoclax * Azacitidine * Cytarabine * Methotrexate * Hydrocortisone * Leucovorin * Dexamethasone * Vincristine * Doxorubicin * Dexrazoxane * Calaspargase pegol * Hydrocortisone

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Andrew E Place, MD, PhD
Dana-Farber Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California San Francisco-Benioff Children'S Hospital
San Francisco, California, United States
Recruiting
Children'S Hospital Colorado
Aurora, Colorado, United States
Recruiting
Children'S Healthcare of Atlanta at Arthur M. Blank Hospital
Atlanta, Georgia, United States
Recruiting
Ann & Robert H Lurie Children'S Hospital of Chicago
Chicago, Illinois, United States
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Andrew E Place, MD, PhD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Azacitidine →Calaspargase pegol →Cytarabine →Dexamethasone →DexrazoxaneDoxorubicin →Asparaginase →Hydrocortisone / lactate →Leucovorin →Methotrexate →Venetoclax →Vincristine →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Mar 2023
Primary completion: 2 Jul 2028
Completion: 2 Jul 2030
Last update posted: 12 Mar 2026
Registered enrollment: 30
Registry id: NCT05292664

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.